Normocalcemic Primary Hyperparathyroidism

Journal of Clinical Densitometry

Volumn 16, Issue 1, 2013, Pages 33-39

  Cusano, Natalie E ^a   Silverberg, Shonni J ^a   Bilezikian, John P ^a  

^a College of Physicians and Surgeons Columbia University ^*  (United States)

Author keywords

Normocalcemic primary hyperparathyroidism; Parathyroid hormone; PTH(1 84)

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; CREATININE; HYDROCHLOROTHIAZIDE; LITHIUM; PARATHYROID HORMONE;

ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL FEATURE; CREATININE CLEARANCE; DISEASE COURSE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHENOTYPE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

CALCIUM; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PARATHYROID HORMONE; PHENOTYPE; VITAMIN D DEFICIENCY;

EID: 84873164399     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2012.12.001     Document Type: Article

References (34)

1. Bilezikian J.P., Silverberg S.J. Primary hyperparathyroidism. Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism 2009, American Society for Bone and Mineral Research, Washington, DC. 7th ed. C. Rosen (Ed.).
2. Bilezikian J.P., Marcus R., Levine M.A. The Parathyroids: Basic and Clinical Concepts 2001, Academic Press, San Diego. 2nd ed.
3. Silverberg S.J., Shane E., Jacobs T.P., et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341:1249-1255.
4. Rubin M.R., Bilezikian J.P., McMahon D.J., et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93:3462-3470.
5. Maruani G., Hertig A., Paillard M., Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003, 88:4641-4648.
6. Silverberg S.J., Bilezikian J.P. " Incipient" primary hyperparathyroidism: a " forme fruste" of an old disease. J Clin Endocrinol Metab 2003, 88:5348-5352.
7. Rao D.S., Wilson R.J., Kleerekoper M., Parfitt A.M. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988, 67:1294-1298.
8. Bilezikian J.P., Silverberg S.J. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2010, 54:106-109.
9. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94:335-339.
10. Cosman F., Shen V., Xie F., et al. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med 1993, 118:337-343.
11. Gallagher J.C., Nordin B.E. Treatment with with oestrogens of primary hyperparathyroidism in post-menopausal women. Lancet 1972, 1:503-507.
12. Selby P.L., Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986, 314:1481-1485.
13. Wills M.R., Pak C.Y., Hammond W.G., Bartter F.C. Normocalcemic primary hyperparathyroidism. Am J Med 1969, 47:384-391.
14. Monchik J.M., Gorgun E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery 2004, 136:1242-1246.
15. Dietary reference intakes for calcium and vitamin D. Dietary Reference Intakes 2011, Committee to Review Dietary Reference Intakes for Vitamin D Calcium Institute of Medicine, The National Academies Press, Washington, DC. A.C. Ross, C.L. Taylor, A.L. Yaktine, H.B. Del Valle (Eds.).
16. Martinez I., Saracho R., Montenegro J., Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997, 29:496-502.
17. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-S201. National Kidney Foundation.
18. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, 76:S1-S130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
19. Walker M.D., Dempster D.W., McMahon D.J., et al. Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab 2012, 97:1501-1507.
20. Paloyan E., Farland M., Pickleman J.R. Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration. JAMA 1969, 210:1243-1245.
21. Mallette L.E., Khouri K., Zengotita H., et al. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab 1989, 68:654-660.
22. Coe F.L., Canterbury J.M., Firpo J.J., Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest 1973, 52:134-142.
23. Balsa J.A., Botella-Carretero J.I., Peromingo R., et al. Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Invest 2008, 31:845-850.
24. Selby P.L., Davies M., Adams J.E., Mawer E.B. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999, 14:652-657.
25. Lowe H., McMahon D.J., Rubin M.R., et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007, 92:3001-3005.
26. Tordjman K.M., Greenman Y., Osher E., et al. Characterization of normocalcemic primary hyperparathyroidism. Am J Med 2004, 117:861-863.
27. Amaral L.M., Queiroz D.C., Marques T.F., et al. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone?. J Osteoporos 2012, 2012:128352.
28. Cakir I., Unluhizarci K., Tanriverdi F., et al. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 2012, 42:419-422.
29. Wade T.J., Yen T.W., Amin A.L., Wang T.S. Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 2012, 36:761-766.
30. Charopoulos I., Tournis S., Trovas G., et al. Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab 2006, 91:1748-1753.
31. Garcia-Martin A., Reyes-Garcia R., Munoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 2012, 42:764-766.
32. Lundgren E., Rastad J., Thrufjell E., et al. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997, 121:287-294.
33. Misra B, McMahon DJ, Silverberg SJ, Bilezikian JP. New data on the impact of renal function on the relationship between 25-hydroxyvitamin D and parathyroid hormone. Proc 30th Annual Meeting of the American Society of Bone and Mineral Research, Montreal, Canada, p1031; 2008.
34. Berger C, Langsetmo L, Hanley D, et al. Relative prevalence of normocalcemic and hypercalcemic hyperparathryoidism in a community-dwelling cohort. Proc 33rd Annual Meeting of the American Society of Bone and Mineral Research, San Diego, California, pSU0173; 2011.